HT
IBRX icon

Headlands Technologies’s ImmunityBio IBRX Stock Holding History

Headlands Technologies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Sell
248,550
-148,620
-37% -$1.12M 0.23% 108
2026
Q1 		$3.05M Buy
+397,170
New +$2.72M 0.35% 48
2024
Q4 		– Sell
-264
Closed -$982 – 1369
2024
Q3 		$982 Buy
264
+242
+1,100% +$1.12K ﹤0.01% 1114
2024
Q2 		$139 Buy
+22
New +$145 ﹤0.01% 1081

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Headlands Technologies's IBRX Position: Q2 2026 in Review

Headlands Technologies reduced its ImmunityBio (IBRX) stake by 37% in Q2 2026, selling an estimated $1.12M and leaving 248,550 shares worth $2.18M. The position accounts for 0.23% of the portfolio, ranked #108.

Headlands Technologies first reported a position in IBRX in Q2 2024 and has held it in 4 quarters since. The position peaked at $3.05M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Headlands Technologies held 248,550 shares of ImmunityBio worth $2.18M as of Q2 2026.
  • Headlands Technologies sold 148,620 ImmunityBio shares in Q2 2026, an estimated $1.12M.
  • ImmunityBio made up 0.23% of Headlands Technologies's portfolio in Q2 2026, its #108 holding.
  • Headlands Technologies first reported a position in ImmunityBio in Q2 2024 and has held it in 4 quarters since.
  • Headlands Technologies's ImmunityBio position peaked at $3.05M in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.